

Synthesis of 2-Hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro- β -carbolines from *N*-Hydroxytryptophans. An Approach to the Eudistomin Series

Ralf Plate,[†] Ruud H. M. van Hout,[†] Helmut Behm,[‡] and Harry C. J. Ottenheijm*[†]

Departments of Organic Chemistry and Crystallography, University of Nijmegen, 6525 Ed Nijmegen, The Netherlands

Received May 21, 1986

Pictet-Spengler condensations of the *N*-hydroxytryptophan ethyl esters **5a** and **5b** with acetals **6a-c** and aldehydes **9a,b** have been evaluated. These reactions provide an access to the 2-hydroxy- β -carbolines **7a-d**, **8a-d**, and **10a,b-12a,b**. Removal of the sulfur protection group of **10b-12b** gave **10c-12c**, respectively. Compound **11b** is a plausible chemosynthetic precursor for the class of eudistomins and may be of biogenetic relevance.


Introduction

Indole alkaloids are prominent secondary metabolites, derived predominantly from the amino acid tryptophan.¹ Recently, we reported² a scheme in which the non-protein amino acid *N*-hydroxytryptophan links *L*-tryptophan to several other non-protein tryptophan derivatives.³ The central significance of *N*-hydroxytryptophan in biotransformation pathways, proposed in that report, is substantiated by the isolation of secondary metabolites containing this *N*-hydroxylated amino acid (e.g., astechrome^{4a}) or containing *N*-hydroxytryptophan derivatives.^{4b} A recent report⁵ described the isolation and structure elucidation of a class of marine alkaloids, i.e., the eudistomins **1**. They are characterized by a *N*-hydroxytryptophan moiety and were found to have a potent activity against the herpes simplex virus, type HSV-1. The eudistomins, possessing an oxathiazepine ring unprecedented in natural products and a 2-oxy-1,2,3,4-tetrahydro- β -carboline moiety, present a distinct challenge for the synthetic organic chemist. They can be considered to be biosynthetically derived from *N*-hydroxytryptophan derivatives **2**, a cysteinyl derivative **3**, and an activated methylene derivative **4**⁶ as indicated in Scheme I. It was our aim to develop a useful, biosynthetically patterned approach to the eudistomins based on this scheme. The approach should feature, we thought, a Pictet-Spengler reaction of a properly protected cysteinyl moiety **3** with an *N*-hydroxytryptophan ester **2** to yield a C(1)-substituted 2-hydroxy-1,2,3,4-tetrahydro- β -carboline moiety. In this reaction the chirality of tryptophan⁷ might be used to control the chirality at C(1) of the β -carboline ring. Subsequently the ethoxycarbonyl group, having fulfilled its function, might be removed.⁸ Here we report that the first part of this approach is viable indeed. The Pictet-Spengler reaction of the *N*-hydroxytryptophan derivative **5** with the acetals **6** and the aldehydes **9** affords the 2-hydroxy-1,2,3,4-tetrahydro- β -carboline derivatives **7** and **8** and **10-12**, respectively.⁹

Results

Pictet-Spengler Reactions of 5a,b with the Acetals 6a-c (Scheme II). The general synthetic potential of the Pictet-Spengler reaction of tryptophan esters or *N*-benzyltryptophan esters with a variety of aldehydes has been demonstrated.¹⁰ At the onset of our investigations no example had been reported, however, of a Pictet-Spengler reaction yielding 2-hydroxy-1,2,3,4-tetrahydro- β -carboline derivatives.⁹ Recently, we reported that the hydroxylamine function of **5a** reacts readily with form-

Scheme I



Scheme II




Table I. 2-Hydroxy-1,2,3,4-tetrahydro- β -carbolines **7**, **8**, and **10-12** from **5**

compd	product ratio	yield, %	¹³ C NMR, δ (decoupled)	
			C(1)	C(3)
7a	7a = 8a	91		
7b			57.3	60.2
8b	1:2	95	58.7	66.7
7c			65.8	60.3
8c	3:2	77	69.0	68.1
7d				
8d	1:1	96		
10a				
11a	1:1:2	53		
12a				
10b			61.2	66.3
11b	1:1:2	54	62.1	62.7
12b			62.3	74.1

aldehyde dimethyl acetal **6a** to yield (91%) the 2-hydroxy-1,2,3,4-tetrahydro- β -carboline **7a**¹¹ (Scheme II).

[†]Department of Organic Chemistry.

[‡]Department of Crystallography.

We found that this reaction is also feasible with higher homologues of the acetal. Treatment of **5a** with the acetals **6b,c** in the presence of $\text{CF}_3\text{CO}_2\text{H}$ yields mixtures of the 2-hydroxy-1,2,3,4-tetrahydro- β -carbolines **7b,c** and **8b,c**, which could be separated by column chromatography. The yields are given in Table I. The product ratios were determined by means of analytical HPLC technique.

The structures of the condensation products and in particular their relative stereochemistry were assigned on the basis of ^{13}C NMR data. It has been noted^{10a-c} that in the off-resonance-decoupled ^{13}C NMR spectra of trans-1,3-disubstituted 1,2,3,4-tetrahydro- β -carbolines the chemical shift values for the C(1) and C(3) atoms are smaller than the values of the corresponding C atoms in the cis isomers. The compression effect, resulting from 1,3-diaxial interactions in the trans isomer, has been invoked to explain this observation.^{10a} Consequently, trans structures **7b,c** were assigned to the isomers showing more shielded C(1) and C(3) carbon atoms in the ^{13}C NMR spectrum. Relevant features of the ^{13}C NMR spectra are given in Table I.

Recently, it has been pointed out¹² that in 1,3-disubstituted 1,2,3,4-tetrahydro- β -carbolines only the C(1) chemical shift is invariably indicative of the stereochemistry; the chemical shift value of the C(3) carbon atom was found to be not reliable for this purpose because it also depends on the N(b) substituent. However, the chemical shifts of C(1) as well as of C(3) in the ^{13}C NMR spectrum of 2-hydroxy-1,2,3,4-tetrahydro- β -carbolines **7b,c** and **8b,c** are a reliable guide to the stereochemistry. Further support for the structure assignment is based on single-crystal X-ray analysis of **11b** (vide infra).

As appears from Table I the reaction of **5** with **6** yields mixtures of trans/cis isomers (i.e., **7** and **8**). Recently Cook et al.^{10b} reported that the Pictet-Spengler condensation occurs in a completely stereospecific fashion when N-






Figure 1. ORTEP drawing of **11b**.

benzyltryptophan esters are employed. Stereoelectronic effects have been employed to explain the stereospecificity of this reaction. Therefore we examined the reaction of O-benzylated *N*-hydroxytryptophan ester **5b**² with **6b**. However, again a cis/trans mixture was found; the ratio of **7d** and **8d** was even 1:1 now. The *O*-benzyl group clearly fails to direct the condensation in a stereospecific fashion.

Pictet-Spengler Reactions of 5a with the Cysteinals 9a and 9b. In an attempt to direct the above results on the preparation of possible eudistomin precursors, the reaction of **5a** with cysteinyl derivatives was studied. Two N,S-protected derivatives of **3** were prepared from L-cysteine, one being the known *S*-benzyl derivative **9a**¹³ and the other the *S*-*p*-methoxybenzyl derivative **9b**.



These aldehydes reacted easily with **5a** in the presence of an acid ($\text{CF}_3\text{CO}_2\text{H}$) to yield mixtures of the 2-hydroxy-1,2,3,4-tetrahydro- β -carbolines **10a-12a** and **10b-12b**, respectively. The diastereomers were separated by flash column chromatography. The product ratio and yields are given in Table I.



Unfortunately, it had to be accepted that the products obtained were racemates; the specific rotations of the product mixtures were zero. Subsequently we observed that the aldehydes **9a** and **9b** racemize under the conditions of their preparation.¹³ It might be worthwhile to point out here, that should homochiral cysteine derivatives be accessible they would be prone to racemization during the acid-induced Pictet-Spengler reaction.

(13) The aldehydes were prepared from the corresponding N,S-protected L-cysteine methyl ester by reduction with diisobutylaluminum hydride according to: Ito, A.; Takahashi, R.; Baba, Y. *Chem. Pharm. Bull.* 1975, 23, 3081. The authors report that cysteinyl derivatives are exceedingly prone to racemization.

(1) For reviews, see: (a) *The Alkaloids—a Biogenetic Approach*; Dalton, D. R., Ed.; Dekker: New York, 1979; p 215. (b) *Indoles*; Saxton, J. E., Ed.; Wiley: New York, 1983; Part IV.

(2) Ottenheijm, H. C. J.; Plate, R.; Noordik, J. H.; Herscheid, J. D. M. *J. Org. Chem.* 1982, 47, 2147.

(3) *N*-hydroxytryptophans have been proposed moreover as intermediates in the glucosinolate formation of Glucobrassicins; see: Møller, B. L. In *Cyanide in Biology*; Vennesland, B., Conn, E. E., Knowles, C. J., Westley, J., Eds.; Academic: London, 1981; p 197. Mahadevan, S. *Annu. Rev. Plant Physiol.* 1973, 24, 69.

(4) Arai, K.; Sato, S.; Shimizu, S.; Nitta, K.; Yamamoto, Y. *Chem. Pharm. Bull.* 1981, 29, 1510. Hootele, C. *Tetrahedron Lett.* 1969, 2713. Robinson, B.; Moorcroft, D. *J. Chem. Soc. C* 1970, 2077. Morita, Y.; Hesse, M.; Schmid, H.; Hofmann, A. *Helv. Chim. Acta* 1962, 45, 611.

(5) Rinehart, K. L.; Kobayashi, J.; Harbow, G. L.; Hughes, R. G.; Mizak, S. A.; Scahill, T. A. *J. Am. Chem. Soc.* 1984, 106, 1524.

(6) For the biochemical transfer of a one-carbon fragment, see: Bieraeugle, H.; Plemp, R.; Hiemstra, H. C.; Pandit, U. K. *Tetrahedron* 1983, 39, 3971 and references cited therein.

(7) The synthesis of optically active *N*-hydroxytryptophan is currently under investigation in our laboratory.

(8) Several methods have been developed to remove the ethoxy-carbonyl function from related systems, e.g.: Tamelen, E. E. van; Olivier, L. K. *J. Am. Chem. Soc.* 1970, 92, 2136. Yamada, S.; Tomioka, K.; Koga, K. *Tetrahedron Lett.* 1976, 61. Yamada, S.; Murato, K.; Shioiri, T. *Tetrahedron Lett.* 1976, 1605. Bobbitt, J. M.; Willes, J. P. *J. Org. Chem.* 1980, 45, 1978. Massiot, G.; Mulamba, T. *J. Chem. Soc., Chem. Commun.* 1983, 1147. Barton, D. H. K.; Herve, Y.; Portier, P.; Thierry, J. *J. Chem. Soc., Chem. Commun.* 1984, 1298.


(9) During the course of this research a related Pictet-Spengler reaction involving *N*-hydroxytryptamine has been reported: Han, S.-Y.; Lakshminantham, M. V.; Cava, M. P. *Heterocycles* 1985, 23, 1671.

(10) (a) Ungemach, F.; Soerens, D.; Weber, R.; Dipierro, M.; Campos, O.; Mokry, P.; Cook, J. M. *J. Am. Chem. Soc.* 1980, 102, 6976. (b) Ungemach, F.; Dipierro, M.; Weber, R.; Cook, J. M. *J. Org. Chem.* 1981, 46, 164. (c) Jawdosiuik, M.; Cook, J. M. *J. Org. Chem.* 1984, 49, 2699. (d) Massiot, G.; Mulamba, T. *J. Chem. Soc., Chem. Commun.* 1984, 1147.

(11) Plate, R.; Hermkens, P. H. H.; Smits, J. M. M.; Ottenheijm, H. C. *J. Org. Chem.* 1986, 51, 309.

(12) Bailey, P. D.; Hollinshead, S. P.; Dauter, Z. *J. Chem. Soc., Chem. Commun.* 1985, 1575.

Scheme III



The relative configurations of the products were established as follows. The structure of **11b** is based on single-crystal X-ray analyses¹⁴ (Figure 1). The substituents at C(1) and C(3) are in a trans relationship.

Subsequently, the off-resonance-decoupled ¹³C NMR spectra of **10b–12b** were compared (see Table I). The cis structure **12b** was assigned to the only compound lacking the compression effect for the C(1) and C(3) carbon atoms (vide supra). Structure **10b** was assigned to the remaining compound—having δ values for the C(1) and C(3) carbon atoms rather similar to those of **11b**; the only difference with **11b** being the relative stereochemistry at the C(α) carbon. Surprisingly only one cis stereoisomer, i.e., **12b**, could be detected. As a consequence we cannot establish the relative stereochemistry of its C(α) carbon atom on the basis of the abovementioned information.

Finally, structures **10a–12a** were assigned by comparison of their ¹H NMR spectra with those of **10b–12b**. Characteristic differences observed between the spectra of **10b**, **11b**, and **12b** were also found in the series **10a–12a**.

When the reaction leading to **10b–12b** was interrupted after 6 h it was found not to be complete. A fourth fraction was isolated consisting of a mixture of two stereoisomers.¹⁵ The ¹H NMR spectrum of this mixture exhibits a pattern typical for indolenines (δ 7.29–6.44, indolenine C(4)C(7)H). So we assigned tentatively structure **14**—a spiro compound—to these two isomers. Treatment of this fourth fraction with CF₃CO₂H in CH₂Cl₂ supports the structure assignment. It caused formation of a mixture of **10b** and **11b**.

This finding may suggest that all of the Pictet–Spengler reactions under consideration proceed via an *N*-hydroxy-spiroindoleninium intermediate **14**, formed via the nitron **13** (Scheme III). It cannot be excluded, however, that this structure **14** only participates in a ring-chain equilibrium (i.e. **13** \rightleftharpoons **14**) without leading itself to 2-hydroxy-1,2,3,4-tetrahydro-β-carbolines.¹⁶

In view of the other reactive functionalities present in the compounds **10–12** the *S*-protecting groups had to be removed as mildly as possible. We found that the method of choice for the preparation of **10c–12c** was treatment of the corresponding *p*-methoxybenzyl derivatives **10b–12b** with freshly prepared (CF₃CO₂)₂Hg¹⁷ in a mixture of aqueous acetic acid (80%) and ethanol containing anisole as a scavenger of the intermediate benzyl cation. The resulting mercuric sulfides were treated with H₂S to liberate the mercaptans **10c–12c** in 50–64% yield.

(14) Behm, H.; Beurskens, P. T.; Plate, R.; Ottenheijm, H. C. *J. Recl. Trav. Chim. Pays-Bas* 1986, 105, 238.

(15) FAB-MS of **14** (7 kV, 1.4 mA), *m/e* (relative intensity) 590 (M + 1, 1), 289 (2), 277 (2), 215 (3), 185 (39), 121 (14), 93 (100). Anal. Calcd for C₃₂H₃₅N₃O₆S (*M*, 589.711): C, 65.18; H, 5.98; N, 7.04. Found: C, 65.04; H, 5.97; N, 7.04.

(16) Grigg, R.; Gunaratne, H. Q. N.; McNaghten, E. *J. Chem. Soc., Perkin Trans. 1* 1983, 185.

(17) Nishimura, O.; Kitada, G.; Fujino, M. *Chem. Pharm. Bull.* 1978, 26, 1576.

Encouraged by these results we anticipated that the next step in our approach to the eudistomin skeleton would be reaction of **11c** with an activated methylene derivative. So far we have not been able, however, to form the oxathiazepine ring system. The three reagents used up to now, i.e., dimethoxy methane, methoxychloromethane, and the one-carbon-unit transfer reagent 1-tosyl-3,4,4-trimethylimidazolidine,⁶ failed to give identifiable products. It is difficult to rationalize this failure, as no literature exists on oxathiazepines. Currently we are investigating whether the formation of this seven-membered heterocycle has to take place prior to or subsequent to the removal of the ethoxycarbonyl function.

Conclusions

The synthesis of **11c** demonstrates the utility of the *N*-hydroxytryptophan derivative **5a** for an approach to eudistomins **1**. The formation of the oxathiazepine ring system in **11c** and the removal of the ethoxycarbonyl group are currently under investigation. When these conversions can be accomplished, a total synthesis of racemic eudistomins seems feasible by using a derivative of **5a**, having the proper substituents in the indole moiety. Recently we have shown that the procedure used for the preparation of **5**—i.e., reaction of indole with a nitrosoolefin—can also be employed for derivatives of **5** having substituents in the indole moiety.

Having optically active **5** at hand, our approach will provide optically active **11c**. We regard this as an essential asset of our approach, as the homochirality of the cysteine derivative is lost during the synthesis of **11c**. As a consequence of which C(α)–C(1) induction is bound to fail. We anticipate therefore that optically active **11c** has to be derived by C(3)→C(1) induction.

¹³C NMR spectroscopy can reliably be employed to assign the stereo structures of the 2-hydroxy-1,2,3,4-tetrahydro-β-carbolines **7**, **8**, and **10–12**.

Experimental Section

Melting points were taken on a Kofler hot stage (Leitz-Wetzlar) and are uncorrected. Ultraviolet spectra were measured with a Perkin-Elmer spectrometer, Model 555.

Proton magnetic resonance spectra were measured on a Varian Associates Model T-60 or a Bruker WH-90 spectrometer. Chemical shifts are reported as δ values (parts per million) relative to tetramethylsilane as an internal standard. ¹³C NMR resonance spectra were measured on a Bruker WP-60 spectrometer. Mass spectra were obtained with a double-focusing VG 7070E spectrometer. Thin-layer chromatography (TLC) was carried out by using Merck precoated silica gel F-254 plates (thickness, 0.25 mm). Spots were visualized with a UV hand lamp, iodine vapor, Cl₂/TDM,¹⁸ cinnamaldehyde/HCl for indole detection,¹⁹ or ninhydrin. A Miniprep LC (Jobin Yvon) was used for preparative HPLC; as stationary phase Merck silica gel H (Type 60) was used. Merck silica gel (Type 60) was used for flash column chromatography. HPLC analysis was performed with solvent delivery system (Spectra Physics Sp 8700), stationary phase (Chrompack Cptm Spher G18250 × 4.6 mm), and MeOH/H₂O, (9/1, v/v) as an eluent.

1-Methyl-2-hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro-β-carbolines [7b (trans) and 8b (cis)]. To a stirred solution of **5a**¹¹ (1 mmol, 250 mg) and **6b** (2 mmol, 180 mg) in dichloromethane (30 mL) was added dropwise CF₃COOH (150 mg). The reaction mixture was monitored by TLC. After the mixture was stirred for 3 days the solvent was evaporated, and the residue was dissolved in dichloromethane and washed with

(18) Arx, E. von; Faupel, M.; Bruggen, M. *J. Chromatogr.* 1976, 120, 224.

(19) Anfaerbereagentien fuer Papier- und Duennschichtchromatographie; Merck; Darmstadt, F.R.G., 1970; p 108.

water. The solution was dried, and the solvent was removed in vacuo. Flash column chromatography (Merck Silica 60, ethyl acetate/*n*-hexane, 1/1, v/v) gave the diastereomers **7b** and **8b**: 90 mg (33%), R_f 0.33 (ethyl acetate/*n*-hexane, 3/2, v/v), and 170 mg (62%), R_f 0.42, respectively.

Compound 7b (trans): mp 165–168 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{\max} 285 (sh), 276, 270 (sh), 220 nm, λ_{\min} 243 nm; EIMS (70 eV), m/e (relative intensity) 274 ([M]⁺, 19), 259 ([M - CH₃]⁺, 8), 257 ([M - OH]⁺, 43), 243 ([C₁₃H₁₁N₂O₃]⁺, 4), 201 ([M - COOC₂H₅]⁺, 17), 183 ([C₁₂H₁₁N₂]⁺, 90), 169 (35), 157 ([C₁₁H₁₁N]⁺, 100), 143 ([C₁₀H₉N]⁺, 23); exact mass calcd for C₁₅H₁₈N₂O₃ 274.1317, found 274.1313; ¹H NMR (90 MHz, CDCl₃) δ 7.89–6.88 (m, 5 H, Ar H and NH), 6.18 (s, 1 H, NOH), 4.51 (q, ³J = 6.9 Hz, 1 H, C(1)H), 4.22 (q, 2 H, OCH₂CH₃), 4.09 (X part of ABX spectrum, ³J_{AX} = 6.5 Hz, ³J_{BX} = 7.8 Hz, 1 H, C(3)H), 3.42–2.89 (AB part of ABX spectrum, 2 H, C(4)H₂), 1.47 (d, 3 H, CHCH₃), 1.24 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.6 (COOC₂H₅), 136.4 (C(8a)), 134.5 (C(9a)), 126.8 (C(4b)), 121.8 (C(7)), 119.6 (C(6)), 118.2 (C(5)), 110.9 (C(8)), 105.7 (C(4a)), 61.2 (OCH₂CH₃), 60.2 (C(3)), 57.3 (C(1)), 21.1 (C(4)), 19.4 (C(1)CH₃), 14.1 (OCH₂CH₃).

Compound 8b (cis): mp 158–160 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{\max} 285 (sh), 275, 270 (sh), 222 nm, λ_{\min} 241 nm; EIMS (70 eV), m/e (relative intensity) 274 ([M]⁺, 28), 259 ([M - CH₃]⁺, 8), 257 ([M - OH]⁺, 10), 215 ([C₁₂H₁₁N₂O₂]⁺, 11), 201 ([M - COOC₂H₅]⁺, 27), 183 ([C₁₂H₁₁N₂]⁺, 11), 157 ([C₁₁H₁₁N]⁺, 100), 143 ([C₁₀H₉N]⁺, 12); exact mass calcd for C₁₅H₁₈N₂O₃ 274.1317, found 274.1321; ¹H NMR (90 MHz, CDCl₃) δ 7.84–6.84 (m, 5 H, Ar H and NH), 6.00 (br s, 1 H, NOH), 4.24 (q, 2 H, OCH₂CH₃), 4.06 (q, ³J = 6.3 Hz, 1 H, C(1)H), 3.79 (X part of ABX spectrum, ³J_{AX} = 8.1 Hz, ³J_{BX} = 8.1 Hz, 1 H, C(3)H), 3.18–2.78 (AB part of ABX spectrum, 2 H, C(4)H₂), 1.53 (d, 3 H, CHCH₃), 1.31 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.6 (COOC₂H₅), 136.0 (C(8a)), 133.3 (C(9a)), 126.0 (C(4b)), 121.5 (C(7)), 119.3 (C(6)), 117.9 (C(5)), 110.6 (C(8)), 105.3 (C(4a)), 66.7 (C(3)), 61.0 (OCH₂CH₃), 58.7 (C(1)), 23.3 (C(4)), 16.7 (C(1)CH₃), 14.0 (OCH₂CH₃).

1-Phenyl-2-hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro- β -carbolines [7c (trans) and 8c (cis)]. To a stirred solution of **5a** (1 mmol, 250 mg) in dichloromethane (30 mL) and **6c** (1.2 mmol, 180 mg) was added CF₃COOH (150 mg) dropwise. After the mixture was stirred for 6 h at room temperature the products **7c** (47%, 160 mg) and **8c** (30%, 100 mg) were isolated as described for **7b** and **8b**.

Compound 7c (trans): mp 195–197 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{\max} 286 (sh), 277, 271 (sh), 220 nm, λ_{\min} 246 nm; EIMS (70 eV), m/e (relative intensity) 336 ([M]⁺, 9), 319 ([M - OH]⁺, 49), 291 ([M - OC₂H₅]⁺, 5), 263 ([M - COOC₂H₅]⁺, 15), 245 ([C₁₇H₁₃N₂]⁺, 100), 244 ([C₁₇H₁₂N₂]⁺, 33), 219 ([C₁₆H₁₃N]⁺, 73), 218 (62), 144 ([C₁₀H₁₀N]⁺, 6); exact mass calcd for C₂₀H₂₀N₂O₃ 336.1474, found 336.1465; ¹H NMR (90 MHz, CDCl₃) δ 7.64–6.94 (m, 10 H, C(5)C(8)H, NH and C₆H₅), 5.93 (s, 1 H, C(1)H), 5.62 (br s, 1 H, NOH), 4.35–4.00 (m, 3 H, OCH₂CH₃ and X part of ABX spectrum, C(3)H), 3.38 and 3.18 (AB part of ABX spectrum, C(4)H₂), 1.24 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.7 (CO), 139.4 (C(1')), 136.8 (C(8a)), 131.8 (C(9a)), 130.1 (C(2') and C(6')), 128.7 (C(3') and C(5')), 128.2 (C(4')), 126.6 (C(4b)), 122.2 (C(7)), 119.8 (C(6)), 118.5 (C(5)), 111.1 (C(8)), 107.5 (C(4a)), 65.8 (C(1)), 61.0 (OCH₂CH₃), 60.3 (C(3)), 22.1 (C(4)), 14.1 (OCH₂CH₃). Anal. Calcd for C₂₀H₂₀N₂O₃ (*M*, 336.391): C, 71.41; H, 5.99; N, 8.33. Found: C, 71.21; H, 6.00; N, 8.26.

Compound 8c (cis): mp 117–119 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{\max} 286 (sh), 276, 271 (sh), 223 nm, λ_{\min} 243 nm; EIMS (70 eV), m/e (relative intensity) 336 ([M]⁺, 14), 319 ([M - OH]⁺, 22), 316 ([C₂₀H₁₆N₂O₂]⁺, 34), 263 ([M - COOC₂H₅]⁺, 15), 245 ([C₁₇H₁₃N₂]⁺, 95), 244 ([C₁₇H₁₂N₂]⁺, 100), 220 (19), 219 ([C₁₆H₁₃N]⁺, 89), 218 (48); exact mass calcd for C₂₀H₂₀N₂O₃ 336.1474, found 336.1742; ¹H NMR (90 MHz, CDCl₃) δ 7.58–7.00 (m, 10 H, C(5)C(8)H, NH, and C₆H₅), 5.62 (br s, 1 H, NOH), 5.00 (br s, 1 H, C(1)H), 4.31 (q, 2 H, OCH₂CH₃), 4.02 (X part of ABX spectrum, ³J_{AX} = 8.8 Hz, ³J_{BX} = 7.0 Hz, 1 H, C(3)H), 3.22 and 3.19 (AB part of ABX spectrum, ³J_{AX} = 8.8 Hz, ³J_{BX} = 7.0 Hz, ²J_{AB} = 10.8 Hz, 2 H, C(4)H₂), 1.33 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 173.0 (CO), 139.3 (C(1')), 136.7 (C(8a)), 132.7 (C(9a)), 129.5 (C(2') and C(6')), 128.6 (C(3'), C(4'), and C(5')), 126.4 (C(4b)), 122.0 (C(7)), 119.7 (C(6)), 118.2 (C(5)), 111.0 (C(8)),

107.0 (C(4a)), 69.0 (C(1)), 68.1 (C(3)), 61.0 (OCH₂CH₃), 25.4 (C(4)), 14.2 (OCH₂CH₃). Anal. Calcd for C₂₀H₂₀N₂O₃ (*M*, 336.391): C, 71.41; H, 5.99; N, 8.33. Found: C, 71.46; H, 6.04; N, 8.30.

1-Methyl-2-(benzyloxy)-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro- β -carbolines [7d (trans) and 8d (cis)]. To a stirred and cooled (0 °C) solution of **5b** (0.6 mmol, 203 mg) and **6b** (1 mL) in dichloromethane was added dropwise CF₃COOH (100 mg). The mixture was allowed to warm to room temperature and stirred for 3 h. Then the solvents were removed in vacuo, and the residue was dissolved into CH₂Cl₂. The resulting solution was washed with brine, dried (Na₂SO₄), and concentrated to dryness to give a mixture of two isomers in a ratio of 1:1 in 96% yield as an oil. Attempts to separate these isomers failed: R_f (**7d** and **8d**) 0.5 (CH₂Cl₂); UV (MeOH) λ_{\max} 286 (sh), 278, 220 nm, λ_{\min} 245 nm; EIMS (70 eV), m/e (relative intensity) 364 ([M]⁺, 17), 205 (17), 291 ([M - COOC₂H₅]⁺, 16), 273 ([M - C₇H₇]⁺, 36), 257 ([M - C₇H₇O]⁺, 51), 243 (38), 183 (51), 157 ([C₁₁H₁₁N]⁺, 100); exact mass calcd for C₂₂H₂₄N₂O₃ 364.1787, found 364.1795.

S-(*p*-Methoxybenzyl)-*N*-(benzyloxycarbonyl)cysteine Aldehyde (9b). To a cooled (–60 °C) and stirred solution of S-(*p*-methoxybenzyl)-*N*-(benzyloxycarbonyl)cysteine methyl ester²⁰ (33 mmol, 13.0 g) in dry toluene (400 mL) was added dropwise diisobutylaluminum hydride (73 mL, 1 M solution in *n*-hexane, Aldrich Chem. Co.) over a period of 1 h in an argon atmosphere. After the mixture was stirred for another 1.5 h at –60 °C, the excess of reagent was decomposed by careful addition of a mixture of ethanol/concentrated aqueous HCl (40 mL, 10/1, v/v). Then water was added (500 mL), and the organic layer was separated. The aqueous layer was washed with ethyl acetate. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and evaporated to give a white solid. Flash column chromatography (hexane/ethyl acetate, 5/2, v/v) gave **9b** (67%, 8.0 g) as an amorphous white solid which was homogeneous on TLC: R_f 0.33 (hexane/ethyl acetate, 3/2, v/v); UV (MeOH) λ_{\max} 281 (sh), 274, 225 nm, λ_{\min} 255, 212 nm; CIMS (100 eV), (relative intensity) m/e 360 ([M + 1]⁺, 5), 358 (2), 268 ([M - CH₂C₆H₅]⁺, 12), 252 ([M - OCH₂C₆H₅]⁺, 6), 251 (10), 250 (67), 241 (6), 212 (6), 211 (36), 149 (14), 121 (100); ¹H NMR (60 MHz, CDCl₃) δ 9.42 (s, 1 H, CHO), 7.33–6.60 (m, 9 H, C₆H₅ and C₆H₄), 5.62 (d, 1 H, NHCO), 5.00 (s, 1 H, CH₂C₆H₅), 4.25 (X part of ABX spectrum, 1 H, CHNH), 3.70 (s, 3 H, OCH₃), 3.60 (s, 2 H, SCH₂C₆H₄), 2.83 and 2.72 (AB part of ABX spectrum, 2 H, SCH₂CH).

1-[1-(*N*-(Benzyloxycarbonyl)amino)-2-(benzylthio)ethyl]-2-hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro- β -carbolines (10a, 11a, and 12a). To a stirred solution of **9a**¹³ (0.9 mmol, 330 mg) and **5a** (0.7 mmol, 182 mg) in CH₂Cl₂ (30 mL) was added dropwise CF₃COOH (3.5 mmol, 400 mg) at room temperature in an argon atmosphere. The reaction was monitored by TLC. After 60 h the reaction mixture was concentrated to dryness. The residue was dissolved in CH₂Cl₂ (80 mL). The resulting solution was washed with water, dried (Na₂SO₄), filtered, and concentrated to dryness to give a yellow oil consisting mainly of three compounds, which were separated by column chromatography (0.5/99.5, MeOH/CH₂Cl₂, v/v). The product ratio of **10a**/**11a**/**12a** determined by analytical HPLC was 1:1:2. Recrystallization (CH₂Cl₂/*n*-hexane) gave 35 mg of **10a** (9%; R_f 0.42; *n*-hexane/ethyl acetate, 2/1, v/v), 70 mg of **11a** (18%; R_f 0.31), and 100 mg of **12a** (26%; R_f 0.39).

Compound 10a: mp 104–106 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{\max} 287 (sh), 275, 220 nm, λ_{\min} 243 nm; CIMS (100 eV), m/e (relative intensity) 560 ([M + 1]⁺, 1), 544 ([M - CH₃]⁺, 3), 542 ([M - OH]⁺, 3), 540 (2) 420 (5), 418 (10), 310 (2), 259 ([C₁₄H₁₅N₂O₃]⁺, 2), 243 (17), 169 (5), 91 (71); ¹H NMR (90 MHz, CDCl₃) δ 8.73 (s, 1 H, N(9)H), 7.53–6.96 (m, 15 H, C(5)C(8)H, SCH₂C₆H₅, OCH₂C₆H₅, NOH), 5.77 (d, 1 H, NHCO), 5.13 (s, 2 H, OCH₂C₆H₅), 4.53 (X part of ABX spectrum, 1 H, SCH₂CH), 4.35 (br s, 1 H, C(1)H), 4.26 (q, 2 H, OCH₂CH₃), 3.79 (X part of ABX spectrum, ³J_{AX} = 5.7 Hz, ³J_{BX} = 10.4 Hz, 1 H, C(3)H), 3.60 (s, 2 H, SCH₂C₆H₅), 3.21–2.38 (2 AB part of ABX spectrum, 4 H, SCH₂CH, C(4)H₂), 1.31 (t, 3 H, OCH₂CH₃).

Compound 11a: mp 174–176 °C (CHCl₃/hexane); UV (MeOH) λ_{\max} 286 (sh), 271, 220 (sh) nm, λ_{\min} 246 nm; CIMS (100 eV), m/e (relative intensity) 560 ([M + 1]⁺, 5), 544 ([M - CH₃]⁺, 4), 542

([M - OH]⁺, 2), 452 ([M - OCH₂C₆H₅]⁺, 2), 418 (6), 259 ([C₁₄H₁₅N₃O₃]⁺, 13), 243 (35), 241 (13), 195 (5), 169 (18), 91 (100); ¹H NMR (90 MHz, CDCl₃) δ 7.56–6.95 (m, 15 H, C(5)C(8)H, N(9)H, OCH₂C₆H₅, SCH₂C₆H₅), 6.16 (s, 1 H, NOH), 5.49 (d, 1 H, NHCO), 5.02 (s, 2 H, OCH₂C₆H₅), 4.91 (d, ³J = 3.9 Hz, 1 H, C(1)H), 4.31–3.89 (2 X parts of ABX spectrum, C(3)H, NCH), 4.13 (q, 2 H, OCH₂CH₃), 3.82 (d, 2 H, SCH₂C₆H₅), 3.38–2.67 (2 AB parts of ABX spectrum, 4 H, C(4)H₂, CHCH₂S), 1.20 (t, 3 H, OCH₂CH₃).

Compound 12a: mp 72–74 °C (ethyl acetate/hexane); UV (MeOH) λ_{max} 286 (sh), 272, 220 (sh) nm, λ_{min} 246 nm; CIMS (100 eV) *m/e* 560 ([M + 1]⁺, 2), 544 ([M - CH₃]⁺, 1), 542 ([M - OH]⁺, 1), 452 ([M - OCH₂C₆H₅]⁺, 1), 259 ([C₁₄H₁₅N₃O₃]⁺, 7), 243 (15), 241 (20), 195 (8), 169 (10), 91 (100); ¹H NMR (90 MHz, CDCl₃) δ 7.56–6.95 (m, 16 H, C(5)C(8)H, N(9)H, NOH, SCH₂C₆H₅, OCH₂C₆H₅), 5.74 (d, 1 H, NHCO), 5.00 (s, 2 H, OCH₂C₆H₅), 4.60 (br s, 1 H, C(1)H), 4.29 (q, 2 H, CH₂CH₃), 3.95–3.64 (2 X parts of ABX spectrum, CHNH, C(3)H), 3.82 (s, 2 H, SCH₂C₆H₅), 3.29–2.64 (2 AB parts of ABX spectrum, 4 H, SCH₂CH, C(4)H₂), 1.33 (t, 3 H, OCH₂CH₃).

1-[1-(N-(Benzyloxycarbonyl)amino)-2-((4-methoxybenzyl)thio)ethyl]-2-hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro-β-carbolines (10b, 11b, and 12b). To a stirred solution of **9b** (22 mmol, 8.0 g) and **5a** (20 mmol, 5.0 g) in CH₂Cl₂ (450 mL) was added dropwise CF₃COOH (53 mmol, 6.0 g) at room temperature in an argon atmosphere. The reaction was monitored by TLC. After 24 h the reaction mixture was concentrated to dryness. The residue was dissolved in CH₂Cl₂ (500 mL). The resulting solution was washed with water, dried (Na₂SO₄), filtered, and concentrated to dryness to give a yellow oil consisting mainly of three compounds, which were separated by means of HPL chromatography (ethyl acetate/hexane, 2/5, v/v). The product ratio of **10b**/**11b**/**12b** determined by analytical HPLC was 1:1:2. Recrystallization (CH₂Cl₂/*n*-hexane) gave 1.3 g of **10b** (11%; *R*_f 0.49; ethyl acetate/*n*-hexane, 1/1, v/v), 1.9 g of **11b** (16%; *R*_f 0.40), and 3.2 g of **12b** (27%; *R*_f 0.47).

Compound 10b: mp 125–127 °C (CH₂Cl₂/*n*-hexane); UV (MeOH) λ_{max} 286 (sh), 275, 220 nm, λ_{min} 246 nm; FAB⁺ mass spectrum (7 kV, 1.4 mA), *m/e* (relative intensity) 590 ([M + 1]⁺, 1), 461 ([C₂₅H₂₃N₃O₄S]⁺, 3), 369 ([C₁₈H₁₅N₃O₃S]⁺, 6), 301 ([C₁₅H₁₅N₃O₂S]⁺, 4), 277 (45), 275 (3), 259 (6), 257 (3), 245 (3), 243 (4), 223 (6), 213 (7), 187 (10), 186 (41), 185 (100), 147 (7), 121 (30); ¹H NMR (90 MHz, CDCl₃) δ 8.51 (br s, 1 H, N(9)H), 7.80–6.50 (m, 14 H, C(5)C(8)H, C₆H₄OCH₃, C₆H₅, NOH), 5.73 (d, 1 H, NHCO), 5.13 (s, 2 H, CH₂C₆H₅), 4.54 (X part of ABX spectrum, 1 H, NCH), 4.34 (br s, 1 H, C(1)H), 4.29 (q, 2 H, OCH₂CH₃), 3.80 (X part of ABX spectrum, 1 H, ³J_{AX} = 5.7 Hz, ³J_{BX} = 10.4 Hz, C(3)H), 3.66 (s, 3 H, OCH₃), 3.60 (s, 2 H, SCH₂C₆H₄), 3.22–2.38 (2 AB parts of ABX spectra, 4 H, CHCH₂S, C(4)H₂), 1.31 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.5 (C(O)OCH₂CH₃), 158.8 (C(O)N), 136.7 (C(8a)), 136.4 (C(9a)), 156.3, 130.2, 130.2, 130.2, 128.5, 128.5, 127.9, 127.9, 127.9, 113.7, 113.7, (C₆H₅, C₆H₄), 126.3 (C(4b)), 122.0 (C(7)), 119.4 (C(6)), 118.0 (C(5)), 111.2 (C(8)), 108.1 (C(4a)), 67.0 (CH₂C₆H₅), 66.3 (C(3)), 61.2 (C(1) and CH₂CH₃), 55.1 (OCH₃), 53.6 (CHCH₂S), 35.6 (SCH₂C₆H₄), 31.9 (CHCH₂S), 24.8 (C(4)), 14.1 (CH₂CH₃). Anal. Calcd for C₃₂H₃₅N₃O₆S (*M*_r 589.711): C, 65.18; H, 5.98; N, 7.13. Found: C, 65.00; H, 5.97; N, 7.06.}}

Compound 11b: mp 128–129 °C (CHCl₃/hexane); UV (MeOH) λ_{max} 286 (sh), 275, 220 nm, λ_{min} 247 nm; FAB⁺ mass spectrum (7 kV, 1.4 mA), *m/e* (relative intensity) 590 ([M + 1]⁺, 6), 450 ([C₂₄H₂₄N₃O₄S]⁺, 2), 418 ([C₂₂H₂₂N₃O₃S]⁺, 3), 333 ([C₁₆H₁₉N₃O₃S]⁺, 3), 302 ([C₁₅H₁₆N₃O₂S]⁺, 3), 299 (30), 285 (4), 273 (4), 269 (5), 259 (21), 185 (35), 169 (26), 129 (10), 121 (53), 115 (21), 93 (100); ¹H NMR (90 MHz, CDCl₃) δ 7.60–6.64 (m, 14 H, C(5)C(8)H, N(9)H, C₆H₄OCH₃, C₆H₅), 6.20 (s, 1 H, NOH), 5.53 (d, 1 H, NHCO), 4.98 (s, 2 H, CH₂C₆H₅), 4.89 (d, ³J = 4.1 Hz, 1 H, C(1)H), 4.40–3.83 (2 X parts of ABX spectrum, 2 H, C(3)H, NHCO), 4.13 (q, 2 H, OCH₂CH₃), 3.73 (s, 3 H, OCH₃), 3.69 (d, 2 H, SCH₂C₆H₄), 3.42–2.51 (2 AB parts of ABX spectrum, 4 H, C(4)H₂, CHCH₂S), 1.18 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.5 (C(O)OCH₂CH₃), 158.8 (C(O)N), 136.7 (C(8a)), 136.4 (C(9a)), 156.3, 131.4, 130.4, 130.2, 130.2, 128.5, 128.5, 128.0, 127.9, 127.9, 114.2, 114.2 (C₆H₅ and C₆H₄), 126.3 (C(4b)), 122.0 (C(7)), 119.4 (C(6)), 118.0 (C(5)), 111.2 (C(8)), 107.7 (C(4a)), 66.8 (CH₂C₆H₅), 62.7 (C(3)), 62.1 (C(1)), 61.2 (CH₂CH₃), 53.3 (CHCH₂S), 36.6 (SCH₂C₆H₄), 35.4 (CHCH₂S), 21.9 (C(4)), 14.0 (CH₂CH₃). Anal. Calcd for C₃₂-

H₃₅N₃O₆S (*M*_r 589.711): C, 65.18; H, 5.98; N, 7.13. Found: C, 64.99; H, 5.93; N, 7.13.

Compound 12b: mp 72–74 °C (ethyl acetate/hexane); UV (MeOH) λ_{max} 285 (sh), 270, 221 nm, λ_{min} 246 nm; FAB⁺ mass spectrum (7 kV, 1.4 mA), *m/e* (relative intensity) 590 ([M + 1]⁺, 1), 461 ([C₂₅H₂₃N₃O₄S]⁺, 1), 369 ([C₁₈H₁₅N₃O₃S]⁺, 3), 277 (9), 259 (2), 215 (1), 187 (2), 186 (10), 185 (100), 183 (2), 167 (2), 121 (3); ¹H NMR (90 MHz, CD₂Cl₂) δ 7.47–6.53 (m, 15 H, C(5)C(8)H, N(9)H, C₆H₄OCH₃, C₆H₅, NOH), 5.60 (d, 1 H, NHCO), 4.87 (s, 2 H, CH₂C₆H₅), 4.49 (br s, 1 H, C(1)H), 4.13 (q, 2 H, OCH₂CH₃), 3.96–3.42 (2 X parts of ABX spectrum, 2 H, NCH, C(3)H), 3.63 (s, 2 H, OCH₃), 3.63 (s, 2 H, SCH₂C₆H₄), 3.14–2.47 (2 AB parts of ABX spectrum, 4 H, CHCH₂S, C(4)H₂), 1.20 (t, 3 H, OCH₂CH₃); ¹³C NMR (15.08 MHz, CDCl₃) δ 172.7 (C(O)OCH₂CH₃), 158.8 (C(O)N), 136.7 (C(8)), 136.3 (C(9a)), 156.9, 130.2, 130.2, 130.2, 128.4, 128.4, 128.0, 127.8, 127.8, 114.1, 114.1 (C₆H₅ and C₆H₄), 126.5 (C(4b)), 122.0 (C(7)), 119.6 (C(6)), 117.8 (C(5)), 111.4 (C(8)), 108.1 (C(4a)), 74.1 (C(3)), 66.8 (CH₂C₆H₅), 62.3 (C(1)), 61.0 (CH₂CH₃), 55.3 (OCH₃), 52.3 (CHCH₂S), 36.4 (SCH₂C₆H₄), 35.2 (CHCH₂S), 21.4 (C(4)), 14.2 (CH₂CH₃).

1-[1-(N-(Benzyloxycarbonyl)amino)-2-mercaptoethyl]-2-hydroxy-3-(ethoxycarbonyl)-1,2,3,4-tetrahydro-β-carbolines (10c, 11c, and 12c). **Compound 10c.** To a stirred solution of **10b** (1.2 mmol, 0.7 g) in a mixture of acetic acid and 80% aqueous ethanol (5/9, v/v) were added freshly prepared¹⁷ (CF₃COO)₂Hg (2.3 mmol, 1.0 g) and anisole (0.5 mmol) as a scavenger. The reaction was monitored by TLC. After 24 h water (100 mL) was added. Then hydrogen sulfide was bubbled through this solution for 1 h. The resulting mercuric sulfide was filtered off and was washed several times with ethanol. Evaporation of the solvents at room temperature in vacuo gave a yellow oil, which was subjected to flash column chromatography (toluene/ethyl acetate/formic acid, 40/1/1, v/v/v). Recrystallization gave **10c** in 50% (0.28 g) yield: mp 98–100 °C (CH₂Cl₂/*n*-hexane); *R*_f 0.60 (toluene/ethyl formate/formic acid, 10/7/3, v/v/v); UV (MeOH) λ_{max} 286 (sh), 277, 271 (sh), 221 nm, λ_{min} 245 nm; CIMS (100 eV), *m/e* (relative intensity) 470 ([M + 1]⁺, 1), 454 ([M - CH₃]⁺, 3), 452 ([M - OH]⁺, 6), 450 ([M - H₂O]⁺, 4), 420 (18), 418 (25), 417 (5), 346 (4), 310 (4), 274 (3), 243 (16), 169 (5), 121 (8); ¹H NMR (90 MHz, CD₂Cl₂) δ 8.93 (s, 1 H, N(9)H), 7.50–6.90 (m, 10 H, C(5)C(8)H, C₆H₅, NOH), 6.04 (d, 1 H, NHCO), 5.09 (s, 2 H, OCH₂C₆H₅), 4.51 (X part of ABX spectrum, 1 H, SCH₂CH), 4.33 (br s, 1 H, C(1)H), 4.18 (q, 2 H, OCH₂CH₃), 3.76 (X part of ABX spectrum, 1 H, C(3)H), 3.24–2.43 (2 AB parts of ABX spectrum, 1 H, SCH₂CH, C(4)H₂), 1.38 (t, ³J = 8.0 Hz, 1 H, SH), 1.27 (t, 3 H, OCH₂CH₃).

Compound 11c. Thiol **11c** was prepared from **11b** (2.5 mmol, 1.5 g) by treatment with (CF₃COO)₂Hg (1.8 g, 4.1 mmol) as described for the preparation of **10c**. Recrystallization gave **11c** in 56% (0.66 g) yield: mp 97–99 °C (CH₂Cl₂/*n*-hexane); *R*_f 0.57 (toluene/ethyl formate/formic acid, 10/7/3, v/v/v); UV (MeOH) λ_{max} 286 (sh), 276, 271 (sh), 221 nm, λ_{min} 245 nm; CIMS (100 eV), *m/e* (relative intensity) 470 ([M + 1]⁺, 1), 454 ([M - CH₃]⁺, 3), 452 ([M - OH]⁺, 8), 450 ([M - H₂O]⁺, 4), 446 (4), 420 (10), 419 (10), 418 (31), 346 (4), 310 (16), 269 (7), 243 (18), 169 (9), 119 (4), 108 (10), 91 (100); ¹H NMR (90 MHz, CDCl₃) δ 8.33 (s, 9 H, N(7)H), 7.53–6.97 (m, 9 H, C(5)C(8)H, C₆H₅), 6.43 (s, 1 H, NOH), 5.62 (d, 1 H, NHCO), 5.00 (d, 1 H, ³J = 4.0 Hz, C(1)H), 4.92 (s, 2 H, OCH₂C₆H₅), 4.34–3.91 (2 X parts of ABX spectrum, 2 H, C(3)H₂, SCH₂CH), 4.09 (q, 2 H, OCH₂CH₃), 3.31–2.60 (2 AB parts of ABX spectrum, 4 H, C(4)H₂, SCH₂CH), 1.58 (t, *J* = 8.0 Hz, 1 H, SH), 1.17 (t, 3 H, OCH₂CH₃).

Compound 12c. Thiol **12c** was prepared from **12b** (5 mmol, 2.9 g) by treatment with (CF₃COO)₂Hg (3.5 g, 8 mmol) as has been described for the preparation of **10c**. Recrystallization gave **12c** in 64% (1.51 g) yield: mp 93–96 °C (CH₂Cl₂/*n*-hexane); *R*_f 0.58 (toluene/ethyl formate/formic acid, 10/7/3, v/v/v); UV (MeOH) λ_{max} 286 (sh), 270, 220 nm, λ_{min} 247 nm; CIMS (100 eV), *m/e* (relative intensity) 470 ([M + 1]⁺, 5), 454 ([M - CH₃]⁺, 5), 452 ([M - OH]⁺, 26), 450 ([M - H₂O]⁺, 4), 420 (8), 418 (9), 346 (4), 344 (4), 312 (6), 310 (4), 274 (14), 259 (7), 243 (19), 169 (8), 139 (11), 121 (19), 91 (100); exact mass calcd for C₂₄H₂₈N₃O₅S (*M* + 1) 470.175, found 470.174; ¹H NMR (90 MHz, CD₂Cl₂) δ 8.62 (s, 1 H, N(9)H), 7.50–6.87 (m, 10 H, C(5)C(8)H, NOH, C₆H₅), 5.87 (d, 1 H, NHCO), 4.88 (s, 2 H, OCH₂C₆H₅), 4.62 (br s, 1 H, C(1)H), 4.18 (q, 2 H, OCH₂CH₃), 3.97–3.58 (2 X parts of ABX spectrum,

2 H, C(3)H, SCH₂CH), 3.24-2.62 (2 AB parts of ABX spectrum, 4 H, C(4)H₂, SCH₂CH), 1.62 (t, *J* = 8.0 Hz, 1 H, SH), 1.27 (t, 3 H, OCH₂CH₃).

Registry No. 5a, 106268-32-0; 5b, 106268-38-6; 6b, 534-15-6; 6c, 1125-88-8; 7b, 106268-33-1; 7c, 106268-35-3; 7d, 106268-50-2;

8b, 106268-34-2; 8c, 106268-36-4; 8d, 106268-37-5; 9a, 89093-55-0; 9b, 106268-40-0; (±)-10a, 106268-41-1; (±)-10b, 106268-44-4; (±)-10c, 106268-47-7; (±)-11a, 106268-42-2; (±)-11b, 106268-45-5; 11c, 106268-48-8; 12a, 106268-43-3; 12b, 106268-46-6; 12c, 106268-49-9; *S*-(*p*-methoxybenzyl)-*N*-(benzyloxycarbonyl)cysteine methyl ester, 106268-39-7.

Application of an Isoxazolidine in a Stereoselective Approach to the Fumitremorgin Series[†]

Ralf Plate,[‡] Pedro H. H. Hermkens,[‡] Helmut Behm,[§] and Harry C. J. Ottenheijm*[‡]

Departments and Organic Chemistry and Crystallography, University of Nijmegen, Toernooiveld, 6525 ED Nijmegen, The Netherlands

Received June 5, 1986


Reduction of the isoxazolidine 5 provides 7, which was coupled with the *N*-protected proline derivative 8. Subsequent deprotection of the amino group affords 11 which undergoes ring closure and dehydration to yield 6 in good yield. The ¹H NMR spectrum of 6 compares unfavorably with that of fumitremorgin C (1), indicating that 6 may be the C(14a) epimer of the natural product.

Introduction

Increased research on mycotoxins, in general over the past 15 years, has led to the discovery of fungal metabolites capable of eliciting sustained or intermittent tremors in vertebrate animals.¹⁻¹⁰ All of these tremorgenic mycotoxins, which share an indole moiety as chemical feature, can be conveniently classified into four groups on the basis of structural relationships. The compounds of one of these groups—the fumitremorgin-verruculogen group, two members of which are given in Scheme I—contain three nitrogen atoms per molecule and are biosynthetically derived from tryptophan, proline, and one or more mevalonic acid moieties.⁴ In efforts to determine the mode of action of fungal tremorgins, it has become apparent that they provide valuable tools in the study of central nervous system functions.¹¹⁻¹⁴ Although particular molecular features responsible for tremorgenic activity in the fumitremorgin-verruculogen group have not been completely identified, there are indications that the conformation and configuration of the dioxopiperazine moiety affects tremorgenic activity.¹⁴

We became interested in the fumitremorgins as attractive synthetic targets because of their biological activity and unique structure. The first target we settled upon was fumitremorgin C (1).^{1,2,4,6} The structure of this fumitremorgin, as first reported in 1977,² contains three chiral carbon atoms. The absolute configuration at C(5a) and C(8) is as depicted in formula 1.²⁻¹⁰ The stereochemistry at C(14a) has not been ascertained¹⁵ and at least in one literature report⁵ the C(8)-substituent has been presented as being a saturated, tertiary alcohol.

Thus, the total synthesis of fumitremorgin C is desirable for at least two reasons. First, a synthesis would confirm the assigned structure and would allow the chirality to be determined. Second, an efficient synthesis of fumitremorgin C constitutes a challenge, because of its unique structure. Despite some attempts at fumitremorgin synthesis,¹⁶⁻²⁰ no member of this class of compounds has yet



been synthesized. Recently we evaluated the cycloaddition chemistry of nitronium 4, obtained from the *N*-hydroxy-

(1) For the isolation report of fumitremorgin C—also called SM-Q—see: Cole, R. J.; Kirksey, J. W.; Dorner, J. W.; Wilson, D. M.; Johnson, J. C.; Johnson, A. N.; Bedell, D. M.; Springer, J. P.; Chexal, K. K.; Clardy, J. C.; Cox, R. H. *J. Agric. Food Chem.* 1977, 25, 826.

(2) Cole, R. J. In *Mycotoxins in Human and Animal Health: Pathotoxicology*; Park Forest South, IL 1977; p 583.

(3) Moreau, C. In *Moulds, Toxins and Food*; Wiley: Chichester, England 1979; p 301.

(4) Yamazaki, M. In *Biosynthesis of Mycotoxins*; Steyn, P. S., Ed.; Academic: London, 1980; p 204 and references cited therein.

(5) Milczewski van, K. E.; Engel, G.; Teuber, M. In *Mycotoxins in Lebensmitteln*; Reiss, J., Ed.; G. Fischer Verlag: New York, 1981; p 44.

(6) Cole, R. J.; Cox, R. H. *Handbook of Toxic Fungal Metabolites*; Academic: London, 1981; p 355.

(7) Cole, R. J. *J. Food Prot.* 1981 44, 715.

(8) Cole, R. J. In *Antinutrients and Natural Toxicants in Foods*; Ory, R. L., Ed.; Food and Nutrition: Westport, CT, 1981; p 17.

(9) Steyn, P. S.; Vleggaar, R.; Rabie, C. J. *Phytochemistry* 1981, 20, 538.

(10) Steyn, P. S.; Vleggaar, R. In *Fortschritte der Chemie organischer Naturstoffe*; Herz, W., Grisebach, H., Kirby, G. W., Tamm, Ch., Eds.; Springer Verlag: Wien, 1985; Vol. 48, p 1.

[†]Dedicated to J. H. Ottenheijm, on the occasion of his 65th birthday.

[‡]Department of Organic Chemistry.

[§]Department of Crystallography.